Paris, November 30 (ots/PRNewswire) – – First New Anti-Arrhythmic Drug to be Approved in the European Union in the Last 10 Years Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the European Commission has granted marketing authorization for Multaq(R) (dronedarone – 400mg Tablets) in all 27 European member states. This approval follows the European [...]
Tag Archive > Atrial Fibrillation
Sanofi-aventis Launches Major New Registry Including Over 10,000 Patients Worldwide With Atrial Fibrillation
Paris, November 16 (ots/PRNewswire) – – The RealiseAF Registry Will Help to Better Define and Understand the Cardiovascular Risk Profile of AF Patients and Characterize Their Cardiovascular Outcomes Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the launch of the RealiseAF registry (Real Life global Survey Evaluating patients with Atrial Fibrillation), an international, cross-sectional, observational [...]
First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes
Orlando, Florida, November 15 (ots/PRNewswire) – Results from the RecordAF registry (REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation), presented today at the Scientific Sessions of the American Heart Association, show that in recently diagnosed and actively treated patients with atrial fibrillation (AF), a rhythm-control strategy provides better short term control of [...]
Edoxaban – ein oraler Gerinnungshemmer in der Entwicklung / Phase-III-Studie über eine neue Behandlungsmöglichkeit gegen Thromboembolie
Barcelona (ots) – Edoxaban, ein oraler Faktor-Xa-Inhibitor, wird derzeit in der zulassungsrelevanten Phase-III-Studie ENGAGE AF-TIMI 48 (Effective aNticoaGulation with Factor xA Next GEneration in Atrial Fibrillation; Deutsch: Wirksame Gerinnungshemmung mit Faktor Xa-Präparaten der nächsten Generation bei Vorhofflimmern) als mögliche neue Behandlung zur Schlaganfallprävention bei Patienten mit Vorhofflimmern geprüft. In Europa leiden etwa 4,5 Millionen Menschen [...]
Edoxaban – next generation oral anticoagulant under investigation to help prevent stroke in patients with atrial fibrillation
Barcelona (ots) – New treatment could offer further option in addition to current standard of care in thromboembolic disease Edoxaban, an oral factor Xa inhibitor, is currently being investigated in the pivotal phase III study ENGAGE AF-TIMI 48 (Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation) as a potential new treatment for stroke [...]
FDA Approves Multaq(R) for Patients With Atrial Fibrillation or Atrial Flutter
Paris (ots/PRNewswire) – – Multaq(R) Approved to Reduce the Risk of Cardiovascular Hospitalization in Patients With Atrial Fibrillation or Atrial Flutter – U.S Commercial Launch Planned for the Summer of 2009 Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets. Patients [...]
Kardiologenverbände von AF AWARE rufen dazu auf, dem Vorhofflimmern mehr Aufmerksamkeit und Aufklärungsarbeit zu widmen
London (ots/PRNewswire) – Laut Umfrage erachten viele Ärzte die Behandlung von Vorhofflimmern als schwierig; Patienten seien sich der Risiken, der Komplexität und der Behandlungsmöglichkeiten dieser am häufigsten auftretenden Herzrhythmusstörung nicht bewusst. Vier führende Patienten- und Ärzteverbände gaben heute die Gründung von AF AWARE (Atrial Fibrillation AWareness And Risk Education – Risikobewusstsein und -aufklärung zum Vorhofflimmern) [...]
EANS-Adhoc: LifeWatch announces the appointments of Dr. Andrea Natale and Dr. John F. Beshai to its Medical Advisory Board
——————————————————————————– Ad-hoc-Mitteilung übermittelt durch euro adhoc mit dem Ziel einer europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich. ——————————————————————————– Forschung/Entwicklung/Medical Advisory Board 12.05.2009 Neuhausen am Rheinfall / Switzerland and Chicago / USA, May 12, 2009 – Card Guard AG’s (SIX Swiss Exchange: CARDG) American subsidiary LifeWatch Services, Inc., the leader in the provision of [...]
New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial With Multaq(R) (dronedarone) in Atrial Fibrillation
Paris (ots/PRNewswire) – – Multaq(R) (dronedarone) Significantly Reduced the Risk of Cardiovascular Hospitalization or Death by 24 Percent in Patients With Atrial Fibrillation Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) announced today that the ATHENA trial was published in the New England Journal of Medicine. The trial showed that Multaq(R) (dronedarone), in [...]
DAIICHI SANKYO leitet Phase-III-Studie zu seinem in Entwicklung befindlichen Faktor-Xa-Inhibitor DU-176b bei Patienten mit Vorhofflimmern ein
TOKYO, MÜNCHEN, Deutschland und EDISON, New Jersey, December 7 (ots/PRNewswire) — – ENGAGE-AF TIMI 48-Studie soll 16.500 Patienten in weltweit über 1.400 Prüfzentren untersuchen DAIICHI SANKYO Company, Limited (TSE: 4568) gab heute bekannt, dass es die zulassungsrelevanten Phase-III-Studien zur Prüfung seines Medikamentenkandidaten DU-176b, eines oralen Faktor-Xa-Inhibitors, bei Patienten mit Vorhofflimmern eingeleitet hat. Die Entwicklung von [...]
RecordAF Registry Will Provide First Global Insight Into Real Life Management of Atrial Fibrillation – A Major Cause of Cardiovascular Death and Hospitalization
New Orleans, November 11 (ots/PRNewswire) – – Baseline Data from RecordAF Presented at American Heart Association’s Scientific Sessions Today Baseline data from the REgistry on Cardiac rhythm disORDers – an international, observational, prospective survey assessing the control of Atrial Fibrillation (RecordAF) – were presented today during the Scientific Sessions of the American Heart Association Congress [...]
Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients With Atrial Fibrillation
New Orleans, Louisiana, November 11 (ots/PRNewswire) – – New Post-Hoc Analysis From Athena Study Showed That Multaq(R) on Top of Standard Therapy Significantly Decreased the Total Number of Hospital Days by 28% in Patients With Atrial Fibrillation or Flutter NEW ORLEANS, Louisiana, November 11 /PRNewswire/ — New data from the landmark ATHENA trial showed that [...]
